The refractory nature of glioblastoma (GBM) is largely attributed to metabolic plasticity and stress adaptation. However, the role of precise mitochondrial calcium ( m Ca 2+ ) flux gating in this context remains elusive. Here, we identify MCUB as a key gatekeeper upregulated in GBM, establishing a restricted m Ca 2+ threshold associated with malignancy. Mechanistically, MCUB limits m Ca 2+ uptake, attenuating pyruvate dehydrogenase activity and enforcing a glycolytic shift. MCUB deficiency triggers m Ca 2+ overload and reactive oxygen species bursts, sensitizing GBM cells to oxidative stress and radiotherapy. Moreover, hypoxia drives this adaptation via HIF-1α, which upregulates MCUB and reinforces its interaction with MCU to tune m Ca 2+ flux. Through high-throughput screening, we identify TF-PPAO as a compound interfering with the MCUB-MCU interaction. TF-PPAO exerts antitumor and radiosensitizing effects in xenografts, patient-derived xenografts (PDXs), and GBM organoids. Our findings reveal MCUB-mediated m Ca 2+ restriction as a mechanism of GBM metabolic adaptation and mitochondrial homeostasis, highlighting MCUB as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: